KeyBanc Remains Positive on Life Sciences as 'Strong' Earning Season Begins with Danaher (DHR) Report

Go back to KeyBanc Remains Positive on Life Sciences as 'Strong' Earning Season Begins with Danaher (DHR) Report

Danaher Reports Second Quarter 2022 Results

July 21, 2022 6:00 AM EDT

WASHINGTON, D.C., July 21, 2022 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the second quarter 2022.  All results in this release reflect only continuing operations unless otherwise noted.

For the quarter ended July 1, 2022, net earnings were $1.7 billion, or $2.25 per diluted common share which represents a 1.5% year-over-year decrease from the comparable 2021 period.  Non-GAAP adjusted diluted net earnings per common share were $2.76 which represents a 12.0% increase over the comparable 2021 period.

Revenues increased 7.5% year-over-year to $7.8 billion. Non-GAAP core revenue... More

Beckman Coulter and Scopio Labs Partner to Accelerate Adoption of Hematology Digital Cell Morphology Platform

July 20, 2022 8:00 AM EDT

BREA, Calif., July 20, 2022 /PRNewswire/ -- Beckman Coulter, a global leader in clinical diagnostics, and Scopio Labs, a medtech company that develops AI-powered workflow solutions, announced today a worldwide partnership to accelerate adoption of Scopio's next generation peripheral blood smear platforms. Scopio's technology employs Full-Field imaging and AI decision support to truly eliminate manual microscopy, while providing laboratory professionals and clinicians a true workflow benefit. With simple to use remote viewing, the Scopio solutions simplify lab operations and improve workflow in a distributed network.... More